Adage Capital Partners’s Cidara Therapeutics CDTX Stock Holding History

Adage Capital Partners’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-263,332	Closed	-$58.2M	–	980
2025 Q4	$58.2M	Sell	263,332 -186,668	-41%	-$30.2M	0.09%	216
2025 Q3	$43.1M	Sell	450,000 -650,000	-59%	-$41.5M	0.07%	265
2025 Q2	$53.6M	Buy	1,100,000 +110,000	+11%	+$2.64M	0.09%	222
2025 Q1	$21.3M	Buy	990,000 +620,046	+168%	+$13.8M	0.04%	396
2024 Q4	$9.94M	Buy	369,954 +327,199	+765%	+$5.32M	0.02%	611
2024 Q3	$460K	Buy	+42,755	New	+$513K	﹤0.01%	816
2018 Q2	–	Sell	-17,800	Closed	-$1.42M	–	741
2018 Q1	$1.42M	Buy	+17,800	New	+$2.43M	﹤0.01%	680

Adage Capital Partners's CDTX Position: Q1 2026 in Review

Adage Capital Partners sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 263,332 shares — an estimated $58.2M sold.

Adage Capital Partners first reported a position in CDTX in Q1 2018 and held it in 7 quarters. The position peaked at $58.2M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Adage Capital Partners reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Adage Capital Partners sold 263,332 Cidara Therapeutics shares in Q1 2026, an estimated $58.2M.
Adage Capital Partners first reported a position in Cidara Therapeutics in Q1 2018 and held it in 7 quarters.
Adage Capital Partners's Cidara Therapeutics position peaked at $58.2M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.